---
title: "Vertex: FDA Grants Breakthrough Therapy Designation To Povetacicept"
description: "Vertex Pharmaceuticals (VRTX) has received Breakthrough Therapy Designation from the FDA for povetacicept, aimed at treating IgAN. This investigational recombinant fusion protein is currently in a glo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258888501.md"
published_at: "2025-09-25T12:37:47.000Z"
---

# Vertex: FDA Grants Breakthrough Therapy Designation To Povetacicept

> Vertex Pharmaceuticals (VRTX) has received Breakthrough Therapy Designation from the FDA for povetacicept, aimed at treating IgAN. This investigational recombinant fusion protein is currently in a global Phase 3 trial named RAINIER. Additionally, Vertex completed enrollment for the IA cohort of the AMPLITUDE trial, which evaluates inaxaplin's effects on kidney function, potentially leading to accelerated approval in the U.S. The company also launched AGLOW, a Phase 2 study for VX-407 targeting ADPKD.

Vertex Pharmaceuticals (VRTX) announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for the treatment of IgAN. Pove is an investigational recombinant fusion protein, and is currently being studied in RAINIER, a global Phase 3 clinical trial in patients with IgAN.

Vertex also announced enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with AMKD. If positive, the IA will serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S.

The company also announced it has initiated AGLOW, a Phase 2 proof-of-concept study of VX-407 for the treatment of ADPKD.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [VRTX.US - Vertex Pharma](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | [Link](https://longbridge.com/en/news/275926557.md) |
| Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit | Sionna Therapeutics presented its strategy for developing next-generation cystic fibrosis therapies focused on NBD1 stab | [Link](https://longbridge.com/en/news/276001201.md) |
| 10:15 ETCAR T-Cell Therapy Market worth $13.78 billion by 2031 \| MarketsandMarkets™ | The CAR T-Cell Therapy Market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, with a CA | [Link](https://longbridge.com/en/news/276065438.md) |
| Zydus: From Generics to Innovation Powerhouse | Zydus Lifesciences has shifted from a generics manufacturer to an innovation-driven pharmaceutical company, focusing on  | [Link](https://longbridge.com/en/news/276109706.md) |
| Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy | Mesoblast Limited (NASDAQ:MESO) shares fell 3.06% to $17.73 in premarket trading after presenting data on Ryoncil at the | [Link](https://longbridge.com/en/news/275763792.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.